Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

被引：0
|
作者：
Mari Yokoi
Daiki Tsuji
Kenichi Suzuki
Yohei Kawasaki
Masahiko Nakao
Hideaki Ayuhara
Yuuki Kogure
Kazuhiko Shibata
Toshinobu Hayashi
Keita Hirai
Kazuyuki Inoue
Toshihiro Hama
Koji Takeda
Makoto Nishio
Kunihiko Itoh
机构：
[1] University of Shizuoka,Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences
[2] Cancer Institute Hospital,Department of Pharmacy, Japanese Foundation for Cancer Research
[3] University of Shizuoka,Department of Drug Evaluation and Informatics, School of Pharmaceutical Sciences
[4] Osaka City General Hospital,Department of Pharmacy
[5] Tokyo Medical University Hospital,Department of Pharmacy
[6] National Hospital Organization Shikoku Cancer Center,Department of Pharmacy
[7] Kouseiren Takaoka Hospital,Department of Medical Oncology
[8] National Hospital Organization Kyushu Medical Center,Department of Pharmacy
[9] Osaka City General Hospital,Department of Clinical Oncology
[10] Cancer Institute Hospital,Department of Thoracic Medical Oncology, Japanese Foundation for Cancer Research
来源：
Supportive Care in Cancer | 2018年 / 26卷
关键词：
Chemotherapy-induced nausea and vomiting (CINV); polymorphism; Cisplatin; Granisetron; Palonosetron; Aprepitant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1505 / 1513
页数：8
相关论文
共 50 条
  • [1] Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy
    Yokoi, Mari
    Tsuji, Daiki
    Suzuki, Kenichi
    Kawasaki, Yohei
    Nakao, Masahiko
    Ayuhara, Hideaki
    Kogure, Yuuki
    Shibata, Kazuhiko
    Hayashi, Toshinobu
    Hirai, Keita
    Inoue, Kazuyuki
    Hama, Toshihiro
    Takeda, Koji
    Nishio, Makoto
    Itoh, Kunihiko
    SUPPORTIVE CARE IN CANCER, 2018, 26 (05) : 1505 - 1513
  • [2] Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.
    Ayuhara, Hideaki
    Tsuji, Daiki
    Yokoi, Mari
    Suzuki, Kenichi
    Kawasaki, Yohei
    Nakao, Masahiko
    Kogure, Yuki
    Shibata, Kazuhiko
    Hayashi, Toshinobu
    Hirai, Keita
    Inoue, Kazuyuki
    Hama, Toshihiro
    Takeda, Koji
    Nishio, Makoto
    Itoh, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] 3-day Aprepitant Plus Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Cisplatin-based Chemotherapy
    Sym, S. J.
    Hong, J.
    Jung, M.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S245 - S245
  • [4] Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting
    Li, Yanying
    Sun, Yu
    Liu, Bin
    Sun, Yi
    Chen, Ping
    Xie, Ke
    Wang, Yan
    Zhu, Jiang
    FUTURE ONCOLOGY, 2022, 18 (20) : 2533 - 2543
  • [5] Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer
    Wang, Wenxian
    Lou, Guangyuan
    Zhang, Yiping
    MEDICINE, 2018, 97 (37)
  • [6] Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation
    Stinson, Jordan
    Chan, Kelvin
    Lee, Justin
    Chow, Ronald
    Cheon, Paul
    Giotis, Angie
    Pasetka, Mark
    Wan, Bo Angela
    Chow, Edward
    DeAngelis, Carlo
    ANNALS OF PALLIATIVE MEDICINE, 2017, 6 : S13 - S20
  • [7] Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving either cisplatin-based chemotherapy regimens or moderately emetogenic chemotherapy
    Annemans, L
    Strens, D
    Lox, E
    Petit, C
    Malonne, H
    VALUE IN HEALTH, 2006, 9 (03) : A107 - A108
  • [8] Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
    Daiki Tsuji
    Megumi Matsumoto
    Yohei Kawasaki
    Yong-I. L. Kim
    Keisuke Yamamoto
    Hidenori Nakamichi
    Yuri Sahara
    Ryo Makuta
    Mari Yokoi
    Takehiro Miyagi
    Kunihiko Itoh
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 73 - 83
  • [9] Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
    Tsuji, Daiki
    Matsumoto, Megumi
    Kawasaki, Yohei
    Kim, Yong-I. L.
    Yamamoto, Keisuke
    Nakamichi, Hidenori
    Sahara, Yuri
    Makuta, Ryo
    Yokoi, Mari
    Miyagi, Takehiro
    Itoh, Kunihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 73 - 83
  • [10] Risk factors of chemotherapy-induced nausea and vomiting in patients with advanced pancreatic cancer receiving modified FOLFIRINOX.
    Shinohara, Akira
    Ikeda, Masafumi
    Irisawa, Ai
    Kobayashi, Misaki
    Udagawa, Ryoko
    Funazaki, Hideki
    Asanagi, Yuko
    Mitsunaga, Shuichi
    Ohno, Izumi
    Takahashi, Hideaki
    Hashimoto, Yusuke
    Umemoto, Kumiko
    Watanabe, Kazuo
    Saito, Shinichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345